Introduction
Hospitalization for treatment of infection is associated with significantly increased risk of venous thromboembolism (VTE), and VTE prophylaxis is an established standard of inpatient care for medical and surgical inpatients after individual risk-benefit assessment. 1, 2 However, a majority of symptomatic VTE occurs in outpatients, and large population based observational data suggests nearly half of 'communityacquired' VTE is in patients hospitalized within the preceding 3 months. 3 This, combined with the recognition that new models of healthcare delivery are reducing hospital admissions, has led to concern that an unmet need exists for VTE risk assessment andprophylaxis in outpatients. 4 Assessing incidence and risk of VTE is not straightforward. Even among medical inpatients enrolled in VTE prophylaxis clinical trials, VTE risk is highly heterogeneous, leaving guideline writers to apply risk assessment models (RAMs) post hoc to published trial results to calculate absolute risk reductions in different patient strata. 1 Considering VTE risk in outpatients will add further heterogenity in VTE risk, and RAMs are only validated for inpatients. Outpatient parenteral antimicrobial therapy (OPAT) is a service which facilitates earlier discharge from, or avoidance of, hospital admission for treatment of infection, so concern about outpatient VTE risk is a pressing issue for OPAT clinicians. Good practice recommendations have suggested that patients attending OPAT should undergo VTE risk assessment and prophylaxis should be considered, 5 but acknowledge there is no published data to quantify VTE incidence in OPAT or inform RAMs. 6 The aim of this study was to establish the incidence of VTE in patients managed through an OPAT service in the west of Scotland and retrospectively assess the predictive performance of a common VTE RAM normally used for inpatients.
Methods
Setting and inclusion criteria NHS Greater Glasgow and Clyde (NHSGG&C) Health Board provides all primary, secondary and tertiary health care to a population of 1.25 million. An OPAT service was established in 2001, and all episodes of OPAT care have been recorded prospectively in an electronic database. This study included consecutive episodes of OPAT where at least one dose of parenteral antimicrobial therapy was administered between May 2009 and May 2012 (based on sample size calculation, see below). Patients on long-term anti-coagulants, those with an established indication for extended, outpatient VTE prophylaxis (i.e. patients referred to OPAT following hip or knee arthroplasty) and those with residence outside NHSGG&C area were excluded.
Data collection and independent variables
Demographic and clinical data including OPAT indication, referral source, complications during OPAT (including VTE), dates of commencing and completing OPAT were extracted from the prospective electronic database. In addition all GG&CHB electronic patient records (including laboratory results portal, national radiology picture archiving and communication system, outpatient clinic attendances, letters between primary care and hospital services, hospital admission records and discharge summaries) were accessed to retrieve or verify data on investigation and diagnosis of VTE in patients who had attended the OPAT service. In cases of patients discharged to OPAT from surgical wards the electronic operation note was reviewed to ascertain the surgeon's plan for VTE prophylaxis post-op. Data on patient risk factors for VTE at time of commencing OPAT were collected to allow retrospective application of the 11 parameter Padua VTE Prediction Score 7 to the cohort.
Outcome variables
The primary outcome was crude incidence of symptomatic VTE during or up to 90 days after completion of OPAT treatment. Number of patients with who were investigated for symptomatic VTE up to 1 year post-OPAT (defined as any evidence of D-dimer assay, Doppler ultrasound scanning, Computer Tomography Pulmonary Angiogram or Ventilation-Perfusion isotope scan), as well as VTE incidence and cause of death up to 1 year following OPAT, were also ascertained.
Hypothesis and power calculation
We hypothesized a VTE crude incidence of 1.5% during or up to 90 days after OPAT completion.
With two tailed alpha set at 0.05, we calculated a sample size of 848 OPAT patient episodes would give 80% power to demonstrate a VTE rate lower than a null hypothesis value of 3.0%. Allowing for an $10% exclusion rate, sample size was set at 940 patient episodes.
Statistical methods
Continuous variables were summarized with mean/ standard deviation or median/inter-quartile range if non-parametric by D'Agostino-Pearson test. Crude incidence of VTE during or up to 90 days was expressed as a percentage with 95% confidence interval for the proportion based on binomial distribution.
Ethics statement
All data were collected as part of routine care. Approval for accessing and collating the data was given by Caldicott Guardian.
Results
During the study period there were 940 patient episodes; 160 were excluded (84 patients post-hip or knee arthroplasty; 58 patients on long-term anticoagulant; 17 patients resident outside NHSGG&C and 1 patient not treated with an antimicrobial) leaving 780 included patient episodes. Median age was 51.5 years, and a majority of patients were treated for skin and soft tissue infection (343, 44.0%) or bone and joint infection (175, 22.4%). Prevalence of VTE risk factors is shown in Table 1 ; 105 (13.5%) patients had a Padua VTE risk score >3.None of the included patients received pharmacological VTE prophylaxis during OPAT treatment. During or up to 90 days following OPAT, 34 (4.4%) were investigated for suspected symptomatic VTE; two proximal lower limb deep vein thromboses were diagnosed, giving VTE incidence during, or up to 90 days post-OPAT episode of 2/780 or 0.26% (95% CI: 0.03-0.92%). Both patients with VTE within 90 days of OPAT were 'low-risk' (score <4) on Padua RAM on day of commencing OPAT. One was a proximal lower right limb DVT in a 55-yearold woman who was 4 months post-open reduction and internal fixation of her right ankle and 5 weeks into OPAT treatment with teicoplanin for infection of this metalwork. She had received low molecular weight heparin (LMWH) prophylaxis while an inpatient prior to discharge to OPAT. The second was a 65-year-old man treated for 6 days in OPAT for left lower limb cellulitis with ceftriaxone following a 2-day admission to hospital during which he had one dose of LMWH. Thirty days after completing OPAT he attended the Emergency Department with a painful left leg and a DVT was confirmed on Doppler ultrasound scanning.
Within 90 days of discharge from OPAT there were eight deaths; of these none were suspected to be related to VTE. There was one intracranial haemorrhage associated death.
In all 780 patients, up to 1 year following OPAT there were an additional three VTEs, giving a total of five VTEs (two deep vein thromboses, two d Padua risk score assigns points for 11 parameters as follows: active cancer = 3/previous VTE = 3/reduced mobility = 3/already known thrombophilic condition = 3/recent (<1 month) surgery = 2/elderly age (>70 years) = 1/heart or respiratory failure = 1/acute myocardial infarction or ischaemic stroke = 1/acute infection = 1/obesity (BMI > 30) = 1/ongoing hormonal treatment = 1. In this cohort, all patients were assumed to not be immobile (as this is defined as 'bed rest with bathroom privileges'), and all scored for presence of acute infection.
pulmonary emboli and one death attributed to pulmonary embolus at 315 days post-OPAT). Rate of VTE appeared constant in the year following OPAT (Figure 1 ).
Discussion
We found a low incidence of VTE among patients who received OPAT to shorten duration of inpatient stay or avoid inpatient admission altogether. The rate of VTE in this cohort-0.26% (95% CI: 0.03-0.92%) during and up to 90 days following OPAT-is comparable to rates of VTE found in low risk medical inpatients for whom prophylaxis is not recommended. 1 It is also a significantly lower rate than has been previously described in recently discharged medical patients. Investigators from McMaster University and Sanofi-Aventis found 2.7% of patients with discharge diagnosis 'severe infectious disease' had VTE within 90 days of discharge in a retrospective review of insurance database records in Canada. 8 In a similar study by investigators from University of California and Sanofi-Aventis, based on claims and hospital billing data, 1.6% of infectious disease patients were diagnosed with VTE in the 180 days post-discharge. 9 The mean age in this study was 67.6 years (although average age in infection sub-groups is not given), while mean age in infection sub-group of the McMaster University study was 57.0 years. This compares to median 51.5 years in our cohort. Risk of VTE rises exponentially with age, 10, 11 and the lower rate of VTE seen in our cohort may be attributable to the selection procedures for OPAT-in particular patients are younger, more mobile and with less comorbidity than general medical discharge populations.
Extending pharmacological VTE prophylaxisbeyond the initial (e.g. 5-14 days) course, for up to $35 days total including beyond inpatient admission-is accepted practice for selected surgical patients, in particular for patients undergoing hip and knee surgery. 2, 12 In our setting, patients attending OPAT after hip or knee surgery are variably receiving extended prophylaxis based on individual risk assessment by the referring surgical team, and were therefore excluded from this study.
In contrast to these post-operative settings, extended prophylaxis in medical patients is not well established: no pharmacological product is licenced for this indication and guidelines recommend against extending prophylaxis in non-surgical patients. 1 The Extended Prophylaxis for Venous Thromboembolism in Acutely Ill Medical Patients with Prolonged Immobilization (EXCLAIM) study 13 is the only relevant randomized control trial published to date. EXCLAIM randomized patients with medical admissions associated with immobility to 28 days enoxaparin or placebo following standard 10 days enoxaparin in both groups. Trial eligibility criteria had to be modified after interim analyses suggested that extended-duration enoxaparin caused net harm in the intervention group. Final results showed absolute risk difference for symptomatic VTE at 28 days was À0.75% (95% CI: À1.19 to À0.32%), while absolute risk difference for major bleeding event was 0.51% (95% CI: 0.12-0.89%). Despite selecting patients with risk factors for VTE, the 90 day VTE rate was 1.1% in the placebo group. The low rate of VTE found in our cohort suggests that extended VTE prophylaxis in OPAT patients would not be associated with substantive absolute risk difference or net clinical benefit.
The low event rate precludes any validation of VTE RAMs in this cohort. It is however of interest that neither of the two patients with VTE within 90 days of OPAT had a Padua Risk Score >3, suggesting that RAMs validated for inpatient populations should be applied to OPAT patient groups with caution.
This study has several limitations. First, being retrospective, data may be incomplete. This may include underestimation of risk factor prevalence, for example, prescription of hormonal treatment may have been missed from the predominantly secondary care sources accessed for this study. Furthermore, any VTEs that were diagnosed and managed entirely outside of NHSGG&C would have been missed by this study, although the exclusion of patients resident outside NHSGG&C should have limited this possibility. Second, although individuals deemed suitable for OPAT are a select patient group, it is likely a large degree of heterogeneity of VTE risk exists within our cohort. This study was not powered to show VTE risk across sub-groups. Finally, this is a single centre study and as such results may reflect the Glasgow OPAT patient selection process; results may not be generalizable to settings with significantly different patient selection. Our results suggest that finding subgroups of OPAT patients who would benefit from VTE prophylaxis in the community would require very large prospective multicentre studies.
Conclusion
Although OPAT reduces frequency and duration of hospital admission and is likely to decrease prescription of pharmacological VTE prophylaxis, we have found a low incidence of VTE among OPAT patients. Our findings suggest that patients selected for OPAT have a markedly different VTE risk profile to in-hospital groups and do not support routine application of inpatient VTE prophylaxis algorithms to patients managed in the community.
